Searching for genetic markers in patients with RP-related autoimmune diseases and bone marrow diseases.
We’ve invested in potentially ground-breaking collaborative research at The University of Texas MD Anderson Cancer Center and NYU Grossman School of Medicine to search for genetic markers in patients with RP-related autoimmune disease and bone marrow diseases.
The powerful research study, led by Dr. Rashmi Kanagal-Shamanna at MD Anderson, Houston, TX, will study the mechanisms of progression of relapsing polychondritis (RP) to myelodysplastic syndromes (MDS) and other hematological (blood-based) malignancies and will focus on mapping the hematologic dynamics over the evolution of disease using state-of-the-art genetic and transcriptomic approaches.
Dr. Kanagal-Shamanna’s research will be conducted in close collaboration with Dr. David B. Beck, M.D., Ph.D., New York University Grossman School of Medicine, New York, NY, who, with the financial support of the RP Foundation, partnered with the NIH to discover a new autoimmune disease named VEXAS Syndrome in 2020.
“We are confident that Drs. Kanagal-Shamanna and Beck’s collaborative study will generate a greater understanding of RP and MDS. Our investment in this novel study represents our commitment to leveraging partnerships that continue to build upon our robust research initiatives and fuel discoveries for RP and related autoimmune diseases.”
This novel research project recently launched. We’ll share updates and results as the team publishes them.
Until recently, there were few options and even fewer resources for patients living with RP. We’re working every day to unlock the mysteries of RP and deliver hope to patients and their families.
